Healionics logo

Healionics

healionics.com

Healionics develops vascular grafts and biomaterial scaffolds for safer and more reliable bloodstream access in dialysis patients with kidney failure. Its STARgraft vascular graft is designed to resist occlusion and infection, aiming to improve patient health and reduce the cost of dialysis care. The company’s STAR biomaterial platform supports tissue regeneration while minimizing scarring and infection in implantable devices.

Facts

HQ
Seattle, WA
Sectors
Medical Device
Founded
2007
Type
Corporation Seattle business license
Employees
9
Registered name
Healionics Corp Seattle business license
Members see funding amounts.
.

Is this your organization? Claim it

Healionics raises $4.7M led by Keiretsu Capital to commercialize STARgraft artificial blood vessel, aims for early‑next‑year launch

Seattle medical device company Healionics raised $4.7 million led by Keiretsu Capital to commercialize STARgraft, a synthetic vascular graft designed to resist occlusion for dialysis patients, and plans a commercial launch early next year. The funding will finance a second human study and FDA clearance efforts; the company also converted $5.2 million of notes and interest into equity.

See all 4 stories, episodes and videos about Healionics.

People

  • Andrew Marshall Executive, Director & Chief Technology Officer
  • Max Maginness Executive, President & Chief Operating Officer
  • Mike Connolly Executive, CEO & Chairman

Online